Campiciano has been an external advisor to Propanc for more than 10 years. Previously, he served as CFO at a startup, had a private accounting business and lectured at Swinburne University in Melbourne, Australia. He’s also a member of the Australian Institute of Public Accountants and is GAAP certified in the US.
The Melbourne-based company is developing new cancer treatments for patients suffering from recurring and metastatic cancer by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers.
Campiciano joins the biopharma as it enters important new phases of growth, with an eye toward uplisting to a US stock exchange.
“As we progress towards submitting a clinical trial application for our First-In-Human study for PRP, we are turning our attention to the next phase in our development as a clinical-stage company, and are very pleased to welcome Carlo’s proven experience and capabilities,” said Propanc CEO James Nathanielsz in a statement.
“This is an exciting time to join the talented Propanc management team and extends my involvement with Propanc from that of an external advisor for more than 10 years, to having a real influence in shaping the future of the business as Chief Financial Officer,” said Campiciano. “I believe my skills and experience with high growth businesses will be valuable in contributing to the next phase of the company’s growth and evolution.”
Contact Paul Curcio at [email protected]
Follow him on Twitter @GoCurcioGo